Neurvati Neurosciences, Inc. – Trademark Portfolio
Entity Type: 03
Neurvati Neurosciences, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 3 Nice Classification classes. Currently, 2 trademarks are registered and 2 are pending. Notable registered marks include NEURVATI and NEURVATI NEUROSCIENCES. The owner is based in New York, NY.
230 Park Avenue, Suite 2830
New York, NY 10169
Showing of trademarks Trademarks
Trademark Classifications
Neurvati Neurosciences, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Neurvati Neurosciences, Inc. have?
Neurvati Neurosciences, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 pending.
What trademark classes does Neurvati Neurosciences, Inc. file in?
Neurvati Neurosciences, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Neurvati Neurosciences, Inc.'s most well-known trademarks?
Neurvati Neurosciences, Inc.'s registered trademark portfolio includes well-known marks such as NEURVATI and NEURVATI NEUROSCIENCES. These are among 2 currently registered trademarks in the portfolio.
What is Neurvati Neurosciences, Inc.'s trademark registration success rate?
Neurvati Neurosciences, Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 2 applications are pending review.